Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (2337)	2/12/2007 11:25:37 AM
From: keokalani'nui	Read Replies (1) \| Respond to of 3158

Adeza to Be Acquired by Cytyc for $24 Per Share Monday February 12, 6:00 am ET Purchase Price of Approximately $450 Million SUNNYVALE, Calif.--(BUSINESS WIRE)--Adeza (NASDAQ:ADZA - News) today announced the signing of a definitive agreement to be acquired by Cytyc Corporation (NASDAQ:CYTC - News), a leading provider of surgical and diagnostic products targeting women's health and cancer diagnostics, for $24 per share, which is a purchase price of approximately $450 million. The acquisition is expected to occur by means of a tender offer for all of the outstanding shares of Adeza common stock. The definitive agreement has been unanimously approved by the Adeza Board of Directors. The acquisition is subject to customary closing conditions and regulatory approvals, and is expected to be completed before the end of March 2007.